1. Introduction {#sec1}
===============

Total parenteral nutrition (TPN) has significantly improved the quality and survival of patients who cannot tolerate enteral nutrition. Despite its numerous medical benefits, TPN is associated with several adverse outcomes, including liver steatosis, cholestasis and fibrosis. There are several different types of lipid emulsions used in TPN; these emulsions vary in their composition of omega-3 and omega-6 fatty acids (FAs), phytosterol concentrations, and vitamin E composition and concentration. The commonly used lipid emulsions are Intralipid®, Omegaven® and Smoflipid®, with Intralipid® composed of lipids rich in omega-6 FAs, Omegaven® of omega-3 FAs and Smoflipid® of both types of lipids. Use of Omegaven® has been associated with decreased incidence of parenteral nutrition-associated liver disease (PNALD)[@bib1].

Lipids administered enterally are absorbed by the enterocyte in the form of a micelle and packaged into chylomicrons for liver metabolism. The lipid particles in parenteral soybean oil are similar in size and structure to the chylomicrons, but primarily contain omega-6 FAs and triglycerides. These lipid particles lack cholesterol or protein. Reduced cholesterol leads to limited lipolysis, resulting in an accumulation of lipid particles in the liver[@bib2].

Omega-3 FAs are thought to exhibit anti-inflammatory effects by causing a shift from omega-6 FA-derived proinflammatory eicosanoids to the anti-inflammatory variety derived from omega-3 FAs[@bib3]. Absorption of phytosterols is limited to 5%--10% when plant products are consumed enterally. However, when given parenterally, phytosterols are fully bioavailable, allowing high, nonphysiologic serum concentrations. It has been shown that high concentrations of serum phytosterols in TPN-dependent children are correlated with PNALD and the severity of cholestasis[@bib2].

The etiology of PNALD is multifactorial[@bib3], and limited clinical studies have shown that oxidative stress is associated with PNALD[@bib4]. Glutathione (GSH), an intracellular peptide present in all tissues with a particularly high concentration in the liver, has diverse functions that include detoxification and antioxidant defense[@bib5]. GSH deficiency contributes to oxidative stress in the liver[@bib6]. The genes involved in the GSH anti-oxidative stress pathway in the liver include, but are not limited to, glutathione *S*-transferase, pi 1 (*Gstp1*), glutathione *S*-transferase, mu 1 (*Gstm1*), glutathione *S*-transferase, mu 3 (*Gstm3*), glutathione *S*-transferase, mu 6 (*Gstm6*), and glutathione peroxidase 3 (*Gpx3*)[@bib7], [@bib8], [@bib9], [@bib10]. Additional genes involved in anti-oxidative stress are NAD(P)H quinone dehydrogenase 1 (*Nqo1),* heme oxygenase 1 (*Ho-1),* metallothionein 1 (*Mt-1),* glutamate-cysteine ligase catalytic subunit *(Gclc),* and glutamate-cysteine ligase modifier subunit (*Gclm)*[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16]. Studies on effects of TPN on the expression of these various genes are currently lacking.

Additionally, there are no reports on the effects of TPN on the expression of genes responsible for drug metabolism. Phase I cytochrome P450 (CYP) enzymes are necessary for detoxification of chemicals including metabolism of drugs[@bib17]. The cytochrome P450 genes involved in drug and xenobiotic metabolism pathways in the liver of mice include, but are not limited to, *Cyp3a11* (human: *CYP3A4*), *Cyp2b10* (human: *CYP2B6*), *Cyp2d9* (human: *CYP2D9*), and *Cyp2f2* (human: *CYP2F1*).

Previously, we performed a microarray to evaluate the changes of expression of genes in the livers of mice receiving Intralipid®^18^. There was downregulation of the expression of several genes involved in GSH metabolism. We also discovered that the expression of genes involved in the drug metabolism pathway were downregulated in mice receiving Intralipid®. The objective of the current study is to determine the mRNA expression and protein levels of genes involved in oxidative stress and drug metabolism in a mouse model of TPN with Intralipid® or Omegaven®. We hypothesize that Intralipid® reduces the expression of genes involved in oxidative stress and drug metabolism. We, additionally, hypothesize that Omegaven® compared to Intralipid, results in less oxidative injury due to higher concentrations of antioxidative omega-3 FAs and lack of phytosterols.

2. Material and methods {#sec2}
=======================

2.1. Animals and treatments {#sec2.1}
---------------------------

Saline, Intralipid® or Omegaven® was administered to 20--25 g male C57BL/6J mice at 6--10 weeks of age. Saline, the components of Intralipid® or Omegaven® were obtained from CAPS pharmacy (Allentown, PA, USA). Mice receiving saline were allowed to feed *ad libitum*. Mice receiving Intralipid® or Omegaven® were kept *nil per os*. In order to administer TPN, mouse jugular veins were cannulated and TPN was infused continuously at 8--10 mL/day. Dosing was determined from previously published works[@bib18]. After 14 days of Intralipid® (*n* = 5), Omegaven® (*n* = 5), or saline (*n* = 6) infusion, mice were euthanized and tissues were harvested for analysis. There was no period of fasting between time of last TPN infusion and sacrifice. All animal experiments were conducted with the approval of the Rutgers University Institutional Animal Care and Use Committee.

2.2. RNA isolation and gene expression measurement {#sec2.2}
--------------------------------------------------

Total RNA was isolated using TRI reagent (Sigma, St. Louis, MO, USA) according to the manufacturer\'s instructions. Reverse transcription was performed on mRNA to make cDNA. Liver mRNA expression of genes was analyzed by RT-qPCR with the details described in our previous publication[@bib19]. The mRNA expression levels of the following genes were measured, including *Gpx3, Gstp1, Gstm1, Gstm3, Gstm6, Nqo1, Ho-1, Mt-1, Gclc, Gclm, Cyp2d9, Cyp2f2, Cyp2b10,* and *Cyp3a11*. The sequences of the primers will be provided upon request.

2.3. GSH level measurement {#sec2.3}
--------------------------

Total, oxidized (glutathione disulfide, GSSG) and reduced (GSH) glutathione in mouse liver lysates were measured using a glutathione kit assay (Cayman Chemical, Ann Arbor, MI, USA), according to supplier\'s instruction. Briefly, 0.1 g mouse liver tissue was homogenated in 1 mL cold GSH assay buffer homogenates, and supernatant after centrifugation at 100,000×*g* for 10 min was used to perform the assay. GSH and GSSH levels were normalized to liver weight.

2.4. Western blot to determining protein levels {#sec2.4}
-----------------------------------------------

Western blot was performed to measure the protein levels of CYP2B10 and CYP3A11 with glyceraldehyde 3-phosphate dehydrogenase (GADPH) as a loading control. Antibodies against mouse CYP2B10 (AB9916) and CYP3A11 (MAB10041) were from EMD Millipore (Burlington, MA, USA).

2.5. Statistical analysis {#sec2.5}
-------------------------

Data are expressed as mean ± SD. A Student\'s *t*-test was performed for statistical significance to show the difference between Intralipid® and saline. One-way ANOVA testing was performed to determine the difference between Intralipid®, saline, and Omegaven® and Tukey testing was performed to determine the difference between the individual groups. A *P* value less than 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Expression of genes in oxidative stress {#sec3.1}
--------------------------------------------

The mRNA levels of several genes involved in GSH metabolism were significantly down-regulated in mice receiving Intralipid® when compared to saline ([Fig. 1](#fig1){ref-type="fig"}). Overall, both Intralipid® and Omegaven® downregulated the expression of these genes consistently: *Gstp1, Gstm1, Gstm3,* and *Gstm6*. However, compared to mice receiving Intralipid®, there was preservation of *Gstm1* with Omegaven® ([Fig. 1](#fig1){ref-type="fig"}).Figure 1RT-PCR results of liver gene expression in mice with Saline (*n* = 6), Intralipid® (*n* = 5) and Omegaven® (*n* = 5). RT-PCR results comparing mRNA levels of *Gpx3*, *Gstp1*, *Gstm1*, *Gstm3*, and *Gstm6*. ∗indicates statistical significance (*P* \< 0.05) between TPN and saline group. ^\#^indicates statistical significance (*P* \< 0.05) between Intralipid® and Omegaven® treatment.Figure 1

A low GSH/GSSG ratio occurs during oxidative stress. Whereas the GSH/GSSG ratio was decreased with Intralipid®, this ratio was preserved with Omegaven® ([Fig. 2](#fig2){ref-type="fig"}). TPN, regardless of lipid solution, significantly downregulated the mRNA levels of *Gclc* and *Gclm* in comparison to saline ([Fig. 3](#fig3){ref-type="fig"}). We measured the mRNA expression of several genes important in anti-oxidative stress. The mRNA levels of Nqo1 were downregulated with the use of Intralipid®, and there was a statistically significant difference noted for Nqo1 mRNA levels when comparing Intralipid® to Omegaven®. Ho-1 expression was increased with the use of both lipid solutions in comparison to saline, as well as when comparing intralipid® to Omegaven®. Mt-1 expression followed the same trend as other genes.Figure 2Total levels of GSH and GSSG, and GSH/GSSG ratio in livers of mice treated with Saline (*n* = 6), Omegaven® (*n* = 5) and Intralipid® (*n* = 5). ∗indicates statistical significance (*P* \< 0.05) between TPN and saline group. ^\#^indicates statistical significance (*P* \< 0.05) between Intralipid® and Omegaven® treatment.Figure 2Figure 3Expression level of liver genes involved in anti-oxidative stress in mice with Saline (*n* = 6), Intralipid® (*n* = 5) and Omegaven® (*n* = 5). RT-PCR results comparing mRNA levels of *Nqo1*, *Ho-1*, *Mt-1*, *Gclc*, and *Gclm* with saline *vs*. Intralipid® *vs*. Omegaven®. ∗indicates statistical significance (*P* \< 0.05) between TPN and saline group. ^\#^indicates statistical significance (*P* \< 0.05) between Intralipid® and Omegaven® treatment.Figure 3

3.2. Expression of genes in drug metabolism {#sec3.2}
-------------------------------------------

Overall, the results comparing the mRNA levels of *Cyp2d9*, *Cyp2f2*, *Cyp2b10*, and *Cyp3a11* revealed a trend of reduction by TPN regardless of lipid composition. There was statistical significance observed for each gene (*Cyp2d9*, *P* \< 0.01; *Cyp2f2*, *P* \< 0.0001; *Cyp2b10*, *P* \< 0.01; and *Cyp3a11*, *P* \< 0.01). Statistically significant downregulation of all four genes was observed on Tukey test comparing saline to Intralipid® (*P* \< 0.05, 0.01, 0.05, 0.01 *for Cyp2d9*, *Cyp2f2*, *Cyp2b10*, *Cyp3a11*, respectively). Statistically significant downregulation of three of the genes was observed on Tukey test comparing saline to Omegaven® (*Cyp2d9*, *P* \< 0.05, *Cyp2f2*, *P* \< 0.001, *Cyp2b10*, *P* \< 0.05). Interestingly, the mRNA levels of *Cyp3a11* (equivalent to CYP3A4 in humans and responsible for the metabolism of majority of medications) were not statistically different from saline when compared to Omegaven® ([Fig. 4](#fig4){ref-type="fig"}).Figure 4Changes in liver drug metabolism gene expression at mRNA levels with Saline (*n* = 6), Intralipid® (*n* = 5) and Omegaven® (*n* = 5). RT-PCR results were shown comparing the mRNA levels of *Cyp2d9*, *Cyp2f2*, *Cyp2b10*, and *Cyp3a11*. ∗indicates statistical significance (*P* \< 0.05) between TPN and saline group. ^\#^indicates statistical significance (*P* \< 0.05) between Intralipid® and Omegaven® treatment.Figure 4

From Western blot analysis of the protein expression levels of CYP3A11 and CYP2B10, there was a statistically significant difference for CYP3A11 levels (*P* \< 0.05), with Omegaven® upregulating the levels of CYP3A11. Furthermore, there was a statistically significant difference in the levels of CYP3A11 when comparing mice receiving Intralipid® to mice receiving Omegaven® ([Fig. 5](#fig5){ref-type="fig"}, *P* \< 0.05).Figure 5Protein levels of drug metabolism enzyme CYP2B10 and CYP3A11 in livers of mice treated with Saline (*n* = 6), Intralipid® (*n* = 5) or Omegaven® (*n* = 5). CYP2B10 and CYP3A11 protein levels were measured by Western blot, and GAPDH was used as the loading control. The levels of protein were quantified with ^\#^indicating statistical significance (*P* \< 0.05) between Intralipid® and Omegaven® treatment.Figure 5

4. Discussion {#sec4}
=============

Reactive oxygen species (ROS) cause cellular injury and have been shown to play an important role in the pathogenesis of PNALD[@bib3]. ROS species are generated continuously in every cell that depends on aerobic metabolism and can be detrimental to cellular function. During cholestasis, bile acids stimulate hepatocytes to produce proinflammatory mediators that attract neutrophils. Neutrophils release ROS that injure hepatocytes, stimulating release of cytokines from Kupffer cells or even directly activating neutrophils[@bib20]. Healthy cells contain several intracellular enzyme systems that limit the production of ROS and maintain extremely low cellular levels of these oxidants[@bib21]. Additionally, cells contain several low-molecular-weight antioxidants, such as GSH, which effectively eliminate ROS[@bib20].

GSH is the most abundant low-molecular-weight thiol, and GSH/glutathione disulfide is the major redox couple in animal cells. GSH exists in all mammalian tissues and is highly concentrated in the liver. Glutathione exists in the thiol-reduced (GSH) and disulfide-oxidized (GSSG) forms, with GSH as the predominant form[@bib5]. We found that the mRNA expression of genes involved in GSH metabolism, including *Gstp1*, *Gstm1*, *Gstm3*, and *Gstm6*, was down-regulated in mice receiving Intralipid®. We speculate that the dysregulation of GSH homeostasis may contribute to PNALD as a result of diminished antioxidative activity in the liver. Compared with mice receiving Intralipid®, there is preservation of one of the GSH pathway genes, *Gstm1*, with use of Omegaven®. We also found that GSH levels were decreased in mice receiving Intralipid®, but increased in those receiving Omegaven®. We speculate that the increased omega-3/omega-6 ratio, decreased phytosterol concentrations, and/or increased vitamin E concentrations in Omegaven are protective against oxidative stress by preserving glutathione and GSH/GSSG ratios. This information may be helpful in identifying future strategies for PNALD intervention.

The difference in lipid compositions of soybean oil parenteral nutrition, Intralipid®, and Omegaven® may also play a role in the development of cholestasis[@bib22]. There is a much higher concentration of vitamin E in Omegaven® in comparison to Intralipid®. Omegaven® also has a lack of both phytosterols and soybean oil, but with a high concentration of fish oil[@bib22]^,^[@bib23]. Of note, the fat compositions of the two lipids are different as well[@bib22]. Omegaven® may be protective against oxidative stress by preserving glutathione and GSH/GSSG ratios. We speculate that the dysregulation of GSH homeostasis may contribute to PNALD as a result of diminished antioxidative activity in the liver. This information may be helpful in identifying future strategies for PNALD intervention.

One of the mechanisms implicated in PNALD is down-regulation of hepatic anti-oxidative pathways and therefore an increase in oxidative injury to the liver. GSH depletion and oxidative stress are important factors in liver injury as well as the pathogenesis of TPN-induced liver abnormalities in weanling rats[@bib24]. After 5 days of TPN, Sokol et al.[@bib25] demonstrated that hepatic GSH levels decreased to 16% of control values. After 8 days of TPN, serum alanine aminotransferase activities were elevated, hepatocellular steatosis was present, and lipid peroxidation of mitochondria was increased compared with control groups. Oxidative stress has been shown to be associated with hepatocellular injury in preterm infants. Weinberger et al.[@bib4] demonstrated that urinary levels of thiobarbituric-acid-reacting substances, indicators of lipid peroxidation and oxidative stress, are correlated with elevated serum transaminase levels.

This information led us to investigate other genes involved in antioxidative stress, such as *Nqo1, Gclc, Gclm, Ho-1,* and *Mt-1*[@bib11]^,^[@bib13]^,^[@bib14]^,^[@bib16]. NQO1 is a flavoprotein with superoxide scavenging activity and it minimizes opportunities for generation of ROS by redox cycling. Induction of NQO1 levels is associated with decreased susceptibilities to oxidative stress. When NQO1 levels are depleted, an increase in oxidative stress is observed[@bib16]. GCL is the rate-limiting step in GSH synthesis and represents a heterodimeric enzyme comprised of a two subunits: GCLC and GCLM[@bib11]. In mammals, HO is the rate-limiting enzyme for the degradation of heme[@bib13].

HO is a catalyst for the oxidative degradation of heme into iron, biliverdin/bilirubin, and carbon monoxide[@bib12]^,^[@bib13]. As an adaptive cellular response to environmental stresses, HO-1 activity is induced. Though the functions of this enzyme are not entirely understood, evidence suggests a role in suppression of inflammation and oxidative stress. The protective effects of HO-1 may be due to its antioxidative product biliverdin/bilirubin, which can scavenge peroxide radicals and inhibit lipid peroxidation[@bib13]. *Ho-1* induction was increased with both Intralipid and Omegaven.

MT-1 is a small cysteine-rich protein that tightly binds and exchanges specific metal ions, particularly zinc[@bib14]. This protein detoxifies heavy metals like mercury and cadmium, while promoting homeostasis of essential metals including copper and zinc. MT-1 also provides antioxidation against ROS, protection against DNA damage and oxidative stress[@bib15]. The antioxidant property of MT-1 enhances in the presence of zinc[@bib14]. Although not statistically significant, mRNA levels of Mt-1 were increased in the presence of Intralipid®.

Therefore, we speculate that reduced expression of *Gclc* and *Gclm* may lead to a decrease in GSH. Preservation of *Nqo1* expression with the use of Omegaven® may lead to decreased susceptibility to oxidative stress. Increased *Ho-1* expression was likely a protective mechanism to suppress oxidative stress. The increase in *Mt-1* expression may be due to a difference in the concentration of copper and zinc in Intralipid® *vs*. Omegaven®.

CYP450 enzymes are important in the detoxification of chemicals and the metabolism of drugs and are subject to regulation in ontogeny[@bib26]. CYP450 enzymes are also essential for the production of steroids, cholesterol, thromboxane A2, and prostacyclins[@bib27]. In humans, there are more than 50 CYP450 enzymes identified. Six of these enzymes metabolize 90 percent of drugs. The two most important enzymes in humans are CYP3A4 and CYP2D6. CYP3A11 is the murine homolog to human CYP3A4^27,28^. A high dosage of *α*-tocopherol leads to increased levels of CYP3A11 in mice. This may induce the drug-metabolizing system to an excessive level, which may lead to an interference with drug metabolism[@bib28].

We found that Intralipid® and Omegaven®, in spite of different lipid composition, reduced the expression of most drug metabolism genes in mice, including *Cyp2d9, Cyp2f2,* and *Cyp2b10*. Although *Cyp3a11* was downregulated by Intralipid®, but not by Omegaven®. This suggests another beneficial effect of Omegaven® in protecting liver functions. Due to the alteration of the expression of CYP450 enzymes, drug metabolism maybe likely affected by the administration of intravenous lipid infusions. Preservation of *Cyp3a11* expression by Omegaven® may be one possible mechanism of its role in preventing the PNALD development.

5. Conclusions {#sec5}
==============

We have shown that the antioxidative defense pathways in the liver are affected by different lipid emulsions in TPN. Compared to Intralipid®, Omegaven® use is associated with preservation of genes essential for detoxification systems in a murine parenteral nutrition model.
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